CORDIS
EU research results

CORDIS

English EN

Bringing a prophylactic Ebola vaccine to licensure

Objective

The overall aim of EBOVAC3 is to support an essential part of remaining clinical and manufacturing activities required for licensure in the European Union (EU) and the United States (US) of a candidate heterologous prime-boost prophylactic vaccine regimen against Ebola virus disease that is under development at Janssen Vaccines & Prevention B.V. The intended target indication is defined as:

“A prime-boost regimen with Ad26.ZEBOV as prime vaccine and MVA-BN®-Filo as boost vaccine indicated for the prevention of Ebola virus disease (EVD) caused by EBOV of the Zaire ebolavirus species in adults and elderly (aged ≥65 years), human immunodeficiency virus (HIV)-infected adults, and children aged ≥1 year.”

Coordinator

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER

Address

Keppel Street
Wc1e 7ht London

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 7 964 171

Participants (4)

Sort alphabetically

Sort by EU Contribution

Expand all

JANSSEN VACCINES & PREVENTION BV

Netherlands

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 4 835 026,21

UNIVERSITEIT ANTWERPEN

Belgium

EU Contribution

€ 8 508 221,25

UNIVERSITY OF SIERRA LEONE

Sierra Leone

EU Contribution

€ 8 095 237,25

Project information

Grant agreement ID: 800176

Status

Ongoing project

  • Start date

    1 June 2018

  • End date

    31 May 2023

Funded under:

H2020-EU.3.1.

  • Overall budget:

    € 50 738 031,96

  • EU contribution

    € 29 402 655,71

Coordinated by:

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER

United Kingdom